A case report on leucine rich glioma inactivated 1 antibody encephalitis
DOI:
https://doi.org/10.18203/2320-6012.ijrms20243405Keywords:
Behavioural changes, Refractory seizure, FBDs, Hyponatremia, Autoimmune encephalitis and LGI 1 antibody autoimmune encephalitisAbstract
Anti-leucine rich glioma inactivated 1 (LGI1) antibody-mediated encephalitis represents an autoantibody mediated variant of limbic encephalitis (LE). We hereby report the case of a 69-year-old female patient experiencing symptoms of giddiness and forgetfulness, which have persisted for the past 90 days. Additionally, she has exhibited behaviours such as irrelevant conversations, confusion, and jerky movements. Upon reviewing her medical history, it was found that she has been diagnosed with hypertension and bronchial asthma, both of which are being managed with ongoing medication. The MRI scan of the brain revealed bilateral, asymmetrical FLAIR hyperintensities within the amygdala and medial temporal lobes (MTL) on both sides, as well as in the left capsuloganglionic region. Further investigations revealed presence of LGI 1 antibodies in both CSF and serum. Subsequently, administration of intravenous immunoglobulin and steroids was initiated, which demonstrated a significant enhancement in her cognitive function. This case study serves to underscore critical elements that ought to prompt the early suspicion of LGI1 encephalitis, such as hyponatremia, autonomic dysfunction, and recurrent refractory seizures. The prompt identification of this condition is correlated with an increased probability of improved clinical results and the maintenance of brain structural integrity, which is intricately connected to the commencement of immunosuppressive treatment.
Metrics
References
Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain 2010;133(9):2734-48.
Durr M, Nissen G, Suhs KW, Schwenkenbecher P, Geis C, Ringelstein M, et al. German network for research on autoimmune encephalitis. CSF findings in acute NMDAR and LGI1 antibody associated autoimmune encephalitis. Neurol Neuro Immunol Neuro Inflamm. 2021;8(6):e1086.
Yong-Won S, Soon-Tae L, Jung-Won S, Jangsup M, Jung-Ah L, Jung-Ick B, et al. VGKC-complex/LGI1-antibody encephalitis: clinical manifestations and response to immunotherapy. J Neuroimmunol 2013;265(1-2):75-81.
Li X, Yuan J, Liu L, Hu W. Antibody-LGI 1 autoimmune encephalitis manifesting as rapidly progressive dementia and hyponatremia: a case report and literature review. BMC Neurol. 2019;19(1):19.
Aurangzeb S, Symmonds M, Knight RK, Kennett R, Wehner T, Irani SR. LGI1-antibody encephalitis is characterised by frequent, multifocal clinical and subclinical seizures. Seizure. 2017;50:14-7.
Gadoth A, Pittock SJ, Dubey D, McKeon A, Britton JW, Schmeling JE, et al. Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients. Ann Neurol 2017;82(1):79-92.
Rodriguez A, Klein CJ, Sechi E, Alden E, Basso MR, Pudumjee S, et al. LGI1 antibody encephalitis: acute treatment comparisons and outcome. J Neurol Neurosurg Psychiatry 2022;93(3):309-15.
Montojo MT, Petit-Pedrol M, Graus F, Dalmau J. Clinical spectrum and diagnostic value of antibodies against the potassium channel related protein complex. Neurologia. 2015;30(5):295-301.
Steriade C, Moosa ANV, Hantus S, Prayson RA, Alexopoulos A, Rae Grant A Electroclinical features of seizures associated with autoimmune encephalitis. Seizure. 2018;60:198-204.
Wu H, Mei F, Liu L, Zhang L, Hao H, Zhang S. Case Report/Case Series: Rare case of anti-LGI1 limbic encephalitis with rapidly progressive dementia, psychiatric symptoms, and frequently seizures: A case report. Medicine. 2021;100(29):e26654.
Blinder T, Lewerenz J. Cerebrospinal fluid findings in patients with autoimmune Encephalitis-A systematic analysis. Front Neurol. 2019;10:804.
Vincent N, Aurélie K, Emmanuelle A, Linda C, Véronique R, Pierre L, et al. Motor cortex and hippocampus are the two main cortical targets in LGI1-antibody encephalitis. Brain. 2016;139(4):1079-93.
McQuillan RF, Bargman JM. Hyponatraemia caused by LGI1-associated limbic encephalitis. NDT Plus. 2011;4(6):424-6.
Roberto KT, Espiritu AI, Fernandez MLL, Gutierrez J C. Electroencephalographic findings in antileucine-rich glioma-inactivated 1 (LGI1) autoimmune encephalitis: A systematic review. Epilepsy Behaviour. 2020;112:107462.
Teng Y, Li T, Yang Z, Su M, Ni J, Wei M, et al. Clinical features and therapeutic effects of anti-leucine-rich glioma inactivated 1 encephalitis: a systematic review. Front Neurol 2022;12:791014.
Wang M, Cao X, Liu Q, Ma W, Guo X, Liu X. Clinical features of limbic encephalitis with LGI1 antibody. Neuropsychiatr Dis Treat. 2017;13:1589-96.
Ghimire P, Khanal UP, Gajurel BP, Karn R, Rajbhandari R, Paudel S, et al. Anti-LGI1, anti-GABABR, and Anti-CASPR2 encephalitis in Asia: A systematic review. Brain Behav 2020;10(10):1-17.
Arjune S, Justine W, Hanka LG, Teresa L, Daniel G, Ernest RSe. Pathognomonic seizures in limbic encephalitis associated with anti-LGI1 antibodies. The Lancet. 2014;383(9933):2018.
Shao X, Fan S, Luo H, Wong TY, Zhang W, Guan H, et al. Brain magnetic resonance imaging characteristics of anti-leucine-rich glioma-inactivated 1 encephalitis and their clinical relevance: a single-center study in China. Front Neurol. 2021;11:618109.
Xiao L, Wei S, Xiaobin Z, Jiechuan R, Guoping R, Chao C, et al. The clinical value of F-FDG-PET in autoimmune encephalitis associated with LGI1 antibody. Front Neurol 2020;11:418.
Pan-Pan zaho, Zhang Y, Gao L, Sun L. Assessing the clinical features of LGI1 antibody encephalitis. Acta Neurol Belg. 2016;116(1):109-12.
Downloads
Published
How to Cite
Issue
Section
